199 related articles for article (PubMed ID: 15560844)
1. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
BMC Cancer; 2004 Nov; 4():83. PubMed ID: 15560844
[TBL] [Abstract][Full Text] [Related]
2. Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Judde JG; Rebucci M; Vogt N; de Cremoux P; Livartowski A; Chapelier A; Tran-Perennou C; Boye K; Defrance R; Poupon MF; Bras-Gonçalves RA
Int J Cancer; 2007 Apr; 120(7):1579-90. PubMed ID: 17205515
[TBL] [Abstract][Full Text] [Related]
3. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
4. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
5. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Von Pawel J
Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
[TBL] [Abstract][Full Text] [Related]
6. Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Liu JT; Li WC; Gao S; Wang F; Li XQ; Yu HQ; Fan LL; Wei W; Wang H; Sun GP
Clin Lung Cancer; 2015 Sep; 16(5):e55-66. PubMed ID: 25979647
[TBL] [Abstract][Full Text] [Related]
7. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Glaysher S; Gabriel FG; Johnson P; Polak M; Knight LA; Parker K; Poole M; Narayanan A; Cree IA;
Br J Cancer; 2010 Aug; 103(5):656-62. PubMed ID: 20700122
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Giaccone G; González-Larriba JL; van Oosterom AT; Alfonso R; Smit EF; Martens M; Peters GJ; van der Vijgh WJ; Smith R; Averbuch S; Fandi A
Ann Oncol; 2004 May; 15(5):831-8. PubMed ID: 15111354
[TBL] [Abstract][Full Text] [Related]
10. New oxaliplatin-based combinations in the treatment of colorectal cancer.
Cassidy J; Hochster H
Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
[TBL] [Abstract][Full Text] [Related]
11. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Fang H; Lin RY; Sun MX; Wang Q; Zhao YL; Yu JL; Tian Y; Wang XY
Asian Pac J Cancer Prev; 2014; 15(24):10967-70. PubMed ID: 25605210
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
Corrie PG; Shaw J; Spanswick VJ; Sehmbi R; Jonson A; Mayer A; Bulusu R; Hartley JA; Cree IA
Br J Cancer; 2005 Jun; 92(11):1997-2003. PubMed ID: 15886706
[TBL] [Abstract][Full Text] [Related]
14. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
15. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
16. Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Van Schaeybroeck S; Karaiskou-McCaul A; Kelly D; Longley D; Galligan L; Van Cutsem E; Johnston P
Clin Cancer Res; 2005 Oct; 11(20):7480-9. PubMed ID: 16243822
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
Abdel-Rahman O; Elsayed Z; Elhalawani H
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Terfloth K; Fluck M; Reitz M
Br J Cancer; 2007 Nov; 97(10):1329-32. PubMed ID: 17971774
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Neale MH; Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
Br J Cancer; 1999 Mar; 79(9-10):1487-93. PubMed ID: 10188895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
